Hyphens Pharma and Favorex Pte Ltd announce commercialisation deal for Alvotech’s proposed ustekinumab biosimilar

Dec 14, 2021

Hyphens Pharma announced that it has signed an exclusive license and supply agreement with DKSH’s subsidiary Favorex Pte Ltd for the commercialisation of Alvotech’s proposed biosimilar ustekinumab in Singapore, Malaysia and the Philippines.

Print Page Mail Article